Status and phase
Conditions
Treatments
About
Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.
Full description
Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.
Trial Participants: Approximately 150 newly diagnosed T2DM patients with randomization 1:1:1 to Metformin XR 500mg twice daily, Dapagliflozin 10 mg daily or Metformin XR 500/Dapagliflozin 5 mg daily
Primary Aim : To evaluate the influence of intervention on vascular function.
Secondary Aims:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
History of ketoacidosis or any other conditions causing acidosis e.g. Alcohol dependence
Has a history of urinary tract infections or is at risk for urinary tract infections (e.g prostatomegaly, vesicoureteric reflux, kidney stones)
Patients on corticosteroids or immunosuppressive agents
Patients known to have HIV infection and/or on anti-retroviral agents
Patients with typical clinical features suggestive of T1DM (young onset with no family history of diabetes or first presentation as DKA were excluded). The endocrinologist (PI or co-I) will look at the patient profile to confirm diagnosis of T2DM.
Has severe liver dysfunction
Considered inappropriate by investigators due to any other reason.
Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
Significant renal impairment.
Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Participants who have a history of Peripheral Arterial Disease or peripheral vascular disease or complains of lower limb claudication pain.
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups
Loading...
Central trial contact
Siti Zaidah; Rinkoo Dalan, MBBS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal